文献速递肝病消化道肿瘤与早癌

综述:肝细胞癌肝移植中的生物标志物——迈向精准医学

Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.
PubMed 文献 · Aliment Pharmacol Ther · 2026-07-03

本综述总结传统与新兴生物标志物在肝细胞癌肝移植中的应用,涵盖蛋白质标志物、基因组特征、转录组与蛋白质组标志物及液体活检,探讨当前挑战与精准医学发展方向。传统标志物广泛用于受者筛选、分期和复发预测,多组学与液体活检标志物可辅助移植前风险分层、降期反应评估、早期复发检测及个体化免疫抑制与辅助治疗指导。

要点

  • 传统标志物(AFP、AFP-L3、PIVKA-II)用于受者筛选、分期和复发预测。
  • 多组学与液体活检标志物可实现无创实时监测,辅助风险分层与早期复发检测。
  • 生物标志物是肝细胞癌肝移植精准医学的核心工具,但标准化与临床应用仍面临挑战。

核心结论

  • 生物标志物是肝细胞癌肝移植精准医学的核心工具,传统标志物联合多组学与液体活检技术有望进一步改善患者预后。

研究设计与样本

  • 本文为综述,检索并汇总近年关于蛋白质生物标志物、基因组特征谱、转录组与蛋白质组标志物及液体活检在肝细胞癌肝移植中应用的文献。

主要发现

  • 传统生物标志物(包括甲胎蛋白、其岩藻糖基化变体AFP-L3及维生素K缺乏或拮抗剂-II诱导蛋白)广泛用于受者筛选、分期和复发预测。
  • 新兴多组学标志物和液体活检标志物提供更深入的分子洞察,并实现无创实时监测。
  • 新兴标志物可辅助移植前风险分层、降期反应评估、早期复发检测,以及指导个体化免疫抑制和辅助治疗。

临床怎么用

  • 传统生物标志物可用于肝细胞癌肝移植受者筛选、分期和复发预测。
  • 多组学与液体活检标志物可辅助移植前风险分层、降期反应评估、早期复发检测及个体化免疫抑制与辅助治疗指导。

局限性

  • 生物标志物在标准化和临床应用方面仍面临挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. For eligible patients, liver transplantation is a curative treatment option, but recurrence after transplantation can severely affect long-term survival rates. Reliable biomarkers are urgently needed to optimise the entire transplantation process. AIMS: This review aims to summarize the role of traditional and emerging biomarkers in the treatment of HCC with liver transplantation, discuss the current challenges, and explore the direction of development in precision medicine. METHOD: We conducted a review of recent literature on protein biomarkers, genomic feature profiles, transcriptomic and proteomic markers, as well as the application of liquid biopsies in HCC liver transplantation. RESULTS: Traditional biomarkers (including alpha-fetoprotein, its fucosylated variant AFP-L3, and protein induced by vitamin K absence or antagonism II) are widely used for recipient screening, staging, and recurrence prediction. Emerging multi-omics markers and liquid biopsy markers provide deeper molecular insights and enable non-invasive real-time monitoring. They assist in pre-transplant risk stratification, downstaging response assessment, early recurrence detection, and guidance of personalised immunosuppression and adjuvant therapy. CONCLUSION: Biomarkers are the core tools for precision medicine in liver transplantation for HCC. Despite challenges in standardization and clinical application, combining traditional biomarkers with multi-omics and liquid biopsy technologies holds promise for further improving patient prognosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ma Y, Li H, Chen H, et al. Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine. Aliment Pharmacol Ther. 2026. PMID: 42394399. doi:10.1111/apt.70793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。